Conference Coverage (ICAAC)

Very-High-Dose Saquinavir Highly Effective

Published in AIDS Weekly, October 2nd, 1995

Very high doses of the HIV protease inhibitor saquinavir (manufactured by Hoffmann-La Roche, Nutley, New Jersey) have a profound antiviral effect in people with intermediate-stage HIV disease.

Saquinavir, also known as Ro 31-8959 or Invirase, was the first of the new class of anti-HIV drugs known as protease inhibitors to reach advanced clinical trials. The arrival of protease inhibitors on the clinical scene has been eagerly awaited as they represent a new front in the war on AIDS: they attack a different point of the HIV replication cycle than currently approved drugs, which are all inhibitors of the HIV reverse transcriptase enzyme.

But early...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (1995-10-02)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry